https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-th/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-vi/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-ms/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/what-does-it-mean-to-be-diagnosed-with-li-fraumeni-syndrome/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/what-does-it-mean-to-be-diagnosed-with-li-fraumeni-syndrome-zh-tw/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/what-does-it-mean-to-be-diagnosed-with-li-fraumeni-syndrome-fr/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/what-does-it-mean-to-be-diagnosed-with-li-fraumeni-syndrome-de/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/what-does-it-mean-to-be-diagnosed-with-li-fraumeni-syndrome-ja/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-zh-tw/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-fr/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-de/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-es/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-ja/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-ar/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-pt/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-ru/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/editors-picks-june-2026-preventing-colorectal-cancer-targeting-neural-cross-talk-to-stop-glioblastoma-recurrence-and-more-id/ 2026-07-11T06:35:08+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-ru/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-id/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-th/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-vi/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-ms/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-zh-tw/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-en/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-fr/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-de/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-ja/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-pt/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-es/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-es/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/fda-notifies-providers-of-safety-related-changes-to-prescribing-information-of-maralixibat-odevixibat-contemporary-pediatrics-ar/ 2026-07-11T06:35:07+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-th/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-vi/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-ms/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-zh-tw/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-fr/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-de/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-ja/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-pt/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-es/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-ar/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-ru/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-id/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-ar/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-th/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-ru/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/%e6%9c%89%e5%85%b3haupt-pharma-amareg-gmbh%e8%8d%af%e5%93%81litalir-500mg%ef%bc%88%e6%89%b9%e5%8f%b74l9808%e3%80%814d8922%ef%bc%89%e5%9b%9e%e6%94%b6%e8%ad%a6%e8%a8%8a%ef%bc%8c%e5%9b%bd%e5%86%85-id/ 2026-07-11T06:35:06+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-de/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-zh-tw/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-ja/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-fr/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-pt/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-de/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-es/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-ja/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-pt/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-es/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-ar/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-ru/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-id/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-th/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-vi/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/tip137-adela-a-double-blind-placebo-controlled-randomized-phase-3-trial-of-elacestrant-everolimus-versus-elacestrant-placebo-in-er-her2-advanced-breast-cancer-abc-patients-with-esr1-mutated-ms/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-vi/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-zh-tw/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/93-monarche-primary-overall-survival-results-of-adjuvant-abemaciclib-endocrine-therapy-for-hr-her2%e2%88%92-high-risk-early-breast-cancer-cancernetwork-ms/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-fr/ 2026-07-11T06:35:05+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-pt/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-ar/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-ru/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-id/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-th/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-vi/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/giredestrant-plus-palbociclib-falls-short-of-statistical-significance-in-phase-3-breast-cancer-trial-targeted-oncology-ms/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-zh-tw/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-en/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-fr/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-de/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-ja/ 2026-07-11T06:35:04+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-es/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-ar/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-ru/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-id/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-th/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-vi/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-ms/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2/ 2026-07-11T06:35:03+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-ar/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-ru/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-id/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-th/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-vi/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-ms/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-zh-t/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-en/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-fr/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-de/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-ja/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-pt/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/%e4%bd%93%e8%83%bd%e7%8a%b6%e6%80%81%e5%b7%ae%e7%9a%844%e4%be%8bnf1%e7%aa%81%e5%8f%98%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e4%b8%89%e7%ba%bf%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb-2-es/ 2026-07-11T06:35:02+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-th/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-vi/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-ms/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-zh-tw/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-fr/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-de/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-zh-tw/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-ja/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-fr/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-pt/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-de/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-es/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-ja/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-pt/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-es/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-ar/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-ru/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer-esmo-daily-reporter-id/ 2026-07-11T06:35:01+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-zh-tw/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-fr/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-de/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-ja/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-pt/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-es/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-ar/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-ru/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-id/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-ar/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-th/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-ru/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-vi/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-id/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/fda-approves-palbociclib-with-trastuzumab-for-breast-cancer-oncology-news-central-ms/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-th/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-vi/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/palbociclib-with-trastuzumab-regimen-approved-by-the-us-fda-for-hr-her2-metastatic-breast-cancer-oncology-central-ms/ 2026-07-11T06:35:00+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-de/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-j/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-ja/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-pt/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-es/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-ar/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-ru/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-id/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-th/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-vi/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-ms/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/metex14%e7%aa%81%e5%8f%98%e8%82%ba%e7%99%8c%e9%9d%b6%e5%90%91%e6%96%b0%e8%8d%af%ef%bc%81%e6%ac%a7%e7%9b%9f%e6%89%b9%e5%87%86%e8%af%ba%e5%8d%8e%e5%bc%ba%e6%95%88met%e6%8a%91%e5%88%b6%e5%89%82tabrectac/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-z/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-e/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-zh-tw/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-f/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/handa-therapeutics-acquires-fda-approved-chronic-myeloid-leukemia-drug-phyrago-dasatinib-tablets-biospace-fr/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-d/ 2026-07-11T06:34:59+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-p/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-a/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-r/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-i/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-t/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-v/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/fda%e6%89%b9%e5%87%86utebzi%ef%bc%9a%e9%a6%96%e6%ac%be%e5%8f%a3%e6%9c%8d%e7%a2%b3%e9%9d%92%e9%9c%89%e7%83%af%e7%b1%bb%e6%8a%97%e7%94%9f%e7%b4%a0%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e5%a4%8d%e6%9d%82-m/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-z/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-e/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-f/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-d/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-j/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-p/ 2026-07-11T06:34:58+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-r/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-i/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-t/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-v/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-m/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-zh-tw/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-en/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-fr/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-de/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/%e4%b8%8a%e5%8d%8a%e5%b9%b4%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86%e5%85%ab%e6%ac%befirst-in-class%e8%8d%af%e7%89%a9%e4%b8%8a%e5%b8%82-%e7%96%bc%e7%97%9b%e3%80%81%e6%84%9f%e6%9f%93%e3%80%81%e7%99%8c-a/ 2026-07-11T06:34:57+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-th/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-vi/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-ms/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/eclinicalmedicine%ef%bc%9a%e9%ab%98%e9%a2%91%e4%b8%8d%e5%8f%af%e9%80%86%e7%94%b5%e7%a9%bf%e5%ad%94%e6%b2%bb%e7%96%97%e8%89%af%e6%80%a7%e5%89%8d%e5%88%97%e8%85%ba%e5%a2%9e%e7%94%9f%e7%96%97%e6%95%88/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/eclinicalmedicine%ef%bc%9a%e9%ab%98%e9%a2%91%e4%b8%8d%e5%8f%af%e9%80%86%e7%94%b5%e7%a9%bf%e5%ad%94%e6%b2%bb%e7%96%97%e8%89%af%e6%80%a7%e5%89%8d%e5%88%97%e8%85%ba%e5%a2%9e%e7%94%9f%e7%96%97%e6%95%88-zh/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/eclinicalmedicine%ef%bc%9a%e9%ab%98%e9%a2%91%e4%b8%8d%e5%8f%af%e9%80%86%e7%94%b5%e7%a9%bf%e5%ad%94%e6%b2%bb%e7%96%97%e8%89%af%e6%80%a7%e5%89%8d%e5%88%97%e8%85%ba%e5%a2%9e%e7%94%9f%e7%96%97%e6%95%88-en/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-ja/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-pt/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-es/ 2026-07-11T06:34:56+00:00 https://keshavmed.com/news/doxypep-%e7%94%a8%e4%ba%8e%e9%a2%84%e9%98%b2%e6%80%a7%e4%bc%a0%e6%92%ad%e6%84%9f%e6%9f%93%ef%bc%9a%e4%b8%8e-chase-cannon-%e5%8d%9a%e5%a3%ab%e7%9a%84%e9%97%ae%e7%ad%94-public-health-insider-ar/ 2026-07-11T06:34:56+00:00